Subscribe to RSS
DOI: 10.1055/s-0040-1715625
Three Individuals with PURA Syndrome in a Cohort of Patients with Neuromuscular Disease
![](https://www.thieme-connect.de/media/neuropediatrics/202105/lookinside/thumbnails/10-1055-s-0040-1715625_202435sc-1.jpg)
Abstract
Pur-α protein (PURA) syndrome manifests in early childhood with core features such as neurodevelopmental and speech delay, feeding difficulties, epilepsy, and hypotonia at birth. We identified three cases with PURA syndrome in a cohort of patients with unexplained muscular weakness, presenting with a predominantly neuromuscular and ataxic phenotype. We further characterize the clinical presentation of PURA syndrome including myopathic facies and muscular weakness as the main clinical symptoms in combination with elevated serum creatine kinase levels. Furthermore, we report two novel variants located in the conservative domains PUR-I and PUR-II. For the first time, we present the muscle biopsies of PURA syndrome patients, showing myopathic changes, fiber size variability, and fast fiber atrophy as the key features. PURA syndrome should be taken into consideration as a differential diagnosis in pediatric patients with unexplained muscle weakness.
Publication History
Received: 07 February 2020
Accepted: 11 June 2020
Article published online:
22 December 2020
© 2020. Thieme. All rights reserved.
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany
-
References
- 1 Daniel DC, Johnson EM. PURA, the gene encoding Pur-alpha, member of an ancient nucleic acid-binding protein family with mammalian neurological functions. Gene 2018; 643: 133-143
- 2 Johnson EM, Kinoshita Y, Weinreb DB. et al. Role of Pur alpha in targeting mRNA to sites of translation in hippocampal neuronal dendrites. J Neurosci Res 2006; 83 (06) 929-943
- 3 Hunt D, Leventer RJ, Simons C. et al; DDD study. Whole exome sequencing in family trios reveals de novo mutations in PURA as a cause of severe neurodevelopmental delay and learning disability. J Med Genet 2014; 51 (12) 806-813
- 4 Lee BH, Reijnders MRF, Abubakare O. et al. Expanding the neurodevelopmental phenotype of PURA syndrome. Am J Med Genet A 2018; 176 (01) 56-67
- 5 Reijnders MRF, Janowski R, Alvi M. et al. PURA syndrome: clinical delineation and genotype-phenotype study in 32 individuals with review of published literature. J Med Genet 2018; 55 (02) 104-113
- 6 Hunt D, Leventer RJ, Simons C. et al; DDD study. Whole exome sequencing in family trios reveals de novo mutations in PURA as a cause of severe neurodevelopmental delay and learning disability. J Med Genet 2014; 51 (12) 806-813
- 7 Johnson EM, Daniel DC, Gordon J. The pur protein family: genetic and structural features in development and disease. J Cell Physiol 2013; 228 (05) 930-937
- 8 Lisi EC, Cohn RD. Genetic evaluation of the pediatric patient with hypotonia: perspective from a hypotonia specialty clinic and review of the literature. Dev Med Child Neurol 2011; 53 (07) 586-599
- 9 Lalani SR, Zhang J, Schaaf CP. et al. Mutations in PURA cause profound neonatal hypotonia, seizures, and encephalopathy in 5q31.3 microdeletion syndrome. Am J Hum Genet 2014; 95 (05) 579-583
- 10 https://www.purasyndrome.org/family . Accessed onNovember 30, 2019